What factors drove the changes in Praxis's revenue and profit?

What guidance did Praxis's management provide for the next earnings period?

What is Praxis's gross profit margin?

What were the key takeaways from Praxis’s earnings call?

Did Praxis beat or miss consensus estimates last quarter?

What is Praxis's latest dividend and current dividend yield?

What were the key takeaways from Praxis's earnings call?

What does Praxis do and what are its main business segments?

- **Pipeline Breakthroughs**: 2025 capped with 2 NDAs, positioning 2026 as execution year for $20B+ CNS portfolio. 
- **Financial Strength**: $1.5B+ cash runway, disciplined R&D/G&A growth (51% YoY). 
- **Commercial Ambition**: Dual launches for ulixacaltamide ($10B) and relutrigine ($5B), with vormatrigine targeting $4B. 
- **Strategic Focus**: Simplified trial designs, rare pediatric drug designations, and FDA-aligned label strategies. 
- **Growth Catalysts**: AAN presentations, POWER1 readout, and elsunersen NDA in 2027.

**【CEO Summary Section】**
- **2025 Milestones**: Submitted NDAs for ulixacaltamide (essential tremor) and relutrigine (SCN2A/8A DEEs), with elsunersen NDA expected in 2027. 
- **Ulixacaltamide**: Phase 3 data shows 58% seizure reduction in focal epilepsy; targeting $10B annual revenue. 
- **Relutrigine**: Demonstrated rapid efficacy in DEEs; potential $5B annual market. 
- **Vormatrigine**: Phase 3 results show 100% seizure reduction in open-label extension; $4B revenue potential. 
- **Elsunersen**: Simplified trial design for DEE; $1B+ annual forecast. 

**【CFO Financial Commentary】**
- **Q4 2025 Results**: Operating expenses $97M (R&D: $77.5M, G&A: $19.5M), up 51% YoY. 
- **Cash Position**: $926M as of Q4, +$621M from January 2026 offering, total $1.5B+ to fund through 2028. 
- **2026 Outlook**: Increased commercial spend for launches, maintaining R&D investment. 

**【Q&A Highlights】**
- **Commercial Prep**: Hiring field teams, inventory build, and disease awareness campaigns for ulixacaltamide and relutrigine. 
- **Label Considerations**: FDA aligns with alternative titration schedules for ulixacaltamide, no additional studies required. 
- **Pipeline Progress**: POWER1 (vormatrigine) readout Q2 2026, EMERALD (relutrigine) enrollment on track, elsunersen trial simplification. 
- **Market Dynamics**: Vormatrigine positioned for first-line use in focal epilepsy; relutrigine targeting rare pediatric populations. 
- **Pricing Strategy**: $50K list price for ulixacaltamide, balancing patient access and commercial viability.

Praxis Precision Medicines, Inc. (PRAX) Q4 2025 Earnings Call Transcript

- **Breakthrough Efficacy**: Vormatrigine achieved 56% median seizure reduction and 22% seizure-free rate in RADIANT, outperforming cenobamate even in high-dose patients.
- **Fast-Acting & Tolerable**: 54% of patients responded by week 1, with only 20% adverse event rate vs. competitors.
- **Strategic Pipeline**: POWER2 (40mg dose added) and POWER3 (monotherapy) studies to expand label, targeting $2-3B hyperrefractory epilepsy market.
- **Mood Benefits**: Observed mood improvements may support broader CNS applications, with formal endpoints added to future trials.

**【CEO Opening Remarks】**
- Announced best-in-disease results for vormatrigine in the RADIANT study, highlighting 56% median seizure reduction and 22% seizure-free rate.
- Emphasized vormatrigine's unique profile: once-daily dosing, fast-acting, no food effect, and no significant drug-drug interactions.
- Discussed the company's robust pipeline with 4 late-stage assets and 5 clinical readouts expected within the next year.
- Highlighted strong recruitment capabilities, with 99 patients screened for the POWER1 study as of July 25, 2025.

**【CSO (Steve Petrou) Study Details】**
- RADIANT study design: 28-day baseline observation followed by 8 weeks of 30mg vormatrigine.
- Key results:
  - 56% median seizure reduction (vs. 30% on cenobamate).
  - 60% responder rate (≥50% reduction), with 22% seizure-free.
  - Rapid onset: 54% response by week 1, 67% by week 8.
- Safety: 23% discontinuation rate, primarily due to background ASM adjustments.
- Notable: 30% of patients were on high-dose cenobamate (≥300mg), yet still achieved 55% response.

**【CEO Future Pipeline Update】**
- POWER2 study (400 patients, 12 weeks) to test 20mg, 30mg, and 40mg doses, with enrollment expected to complete in 2026.
- Added 40mg dose arm based on RADIANT modeling for potential higher efficacy.
- POWER3 study (monotherapy) to initiate in early 2026, targeting refractory epilepsy patients transitioning off background ASMs.
- Highlighted mood improvement observations in RADIANT, leading to inclusion of depression/mood endpoints in POWER2.

**【Q&A Highlights】**
- **Efficacy Across Background Therapies**: Consistent response rates (55-57%) across sodium channel blockers, SV2A modulators, and cenobamate.
- **Discontinuation Rate Insights**: 6 patients with proactive background ASM reduction had no AEs or discontinuations.
- **POWER1 Enrollment**: 99 patients screened as of July 25, with final data expected by year-end 2025.
- **Safety Profile**: Vormatrigine AE rate (20%) significantly lower than competitors, with no meaningful drug-drug interactions.
- **Market Potential**: $2-3B addressable market for hyperrefractory epilepsy, with vormatrigine uniquely positioned for monotherapy.


Actual	-13.05	-10.65	-13.2	-15	-19.5	-22.65	-19.8	-14.4	-13.05	-10.65	-7.35	-2.7	-2.97	-2.84	-1.74	-2.75	-2.94	-3.29	-3.31	-3.5
Forecast	-6.1	-9.99	-10.125	-14.01	-16.225	-19.575	-19.475	-13.29	-11.7638	-11.775	-9.84	-3.9	-3.0517	-2.0829	-2.3149	-1.989	-2.8474	-3.2072	-3.2469	-3.1009
Surprise	-113.93%	-6.61%	-30.37%	-7.07%	-20.18%	-15.71%	-1.67%	-8.35%	-10.93%	+9.55%	+25.30%	+30.77%	+2.68%	-36.35%	+24.83%	-38.26%	-3.25%	-2.58%	-1.94%	-12.87%

Actual	0	0	0	0	0	0	0	0	0	683.00K	800.00K	500.00K	500.00K	415.50K	357.00K	301.00K	7.48M	0	0	0
Forecast	0	0	0	0	0	0	0	0	0	0	0	0	0	1.88M	931.22K	328.56K	398.48K	203.44K	209.51K	66.67K
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-77.94%	-61.66%	-8.39%	+1777.53%	-100.00%	-100.00%	-100.00%

PRAX

PRAX fundamentals

PRAX Q4 2025 Earnings

Earnings Call

You can ask Aime

PRAX

PRAX fundamentals

PRAX Q4 2025 Earnings

Earnings Call

PRAX Earnings Call Summary for Q4/20258:00 AM on Feb 19, 2026

PRAX Earnings Call Summary for Q2/20258:30 AM on Aug 4, 2025

PRAX Earnings Call Summary for Q1/20258:30 AM on May 2, 2025

PRAX Earnings Call Summary for Q4/2024 Mar 28, 2026

PRAX Earnings Call Summary for Q3/20241:00 PM on Nov 6, 2024

You can ask Aime